Navigation Links
TauRx Pharmaceuticals Receives $10.5m Follow-On Investment from Dundee Corporation
Date:3/4/2013

Dundee made its initial investment of USD20m in TauRx in September 2011.  Ned Goodman , President and Chief Executive Officer of Dundee, said: "TauRx has made good use of our initial investment, gaining regulatory clearance to initiate its Phase 3 study program for LMTX™ and establishing a network of experienced service providers to support the studies.  With the first patients now being enrolled into each of the three studies, and with the recent substantial strategic investment from the Genting Berhad group, this seems a highly opportune time to exercise the option we were granted by TauRx at the time of the initial investment and maintain Dundee's 5% interest in this commercially and scientifically promising company."

Professor Claude Wischik , Executive Chairman and Co-Founder of TauRx, said: "It is particularly gratifying to receive this follow-on investment from Dundee.  It made its initial investment at a time of critical importance to the development of both TauRx and our Tau aggregation inhibitor, LMTX™, and we see this additional investment of USD10.5m as a welcome vote of confidence in the commercial potential of our technology from a highly experienced investor.  We continue to believe strongly that Tau aggregation inhibition is the most promising approach to the long-term treatment of AD and other Tau-opathies such as bvFTD.  With expanding patient populations throughout the world due to an aging population, and with products based on beta-amyloid clearance still producing disappointing results in clinical studies, it is now critically important for healthcare systems, patients, their families and their careers to bring an effective treatment for these devastating diseases to market."

About TauRx Therapeutics:

TauRx Therapeutics Ltd was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases based on an entirely new approach which targets aggregates of abnormal fibres of Tau protein that form inside nerve cells in the brain. The TauRx team have since discovered that LMTX™ could also have beneficial effects in several other neurodegenerative diseases associated with Tau pathology, as well as other protein aggregation disorders including Parkinson's, Huntington's and Frontotemporol Dementia [FTD-Pick's Disease]. The TauRx corporate headquarters are in Singapore and its primary research facilities are in Aberdeen, Scotland.

About Dundee Corporation:

Dundee Corporation is a Canadian independent publicly traded asset management company listed on the Toronto Stock Exchange ("TSX") under the symbol "DC.A". Asset management activities are focused in the areas of the corporation's core competencies and include resources, real estate and infrastructure, and more recently, the agriculture sector. These activities are carried out by Dundee's wholly owned subsidiary, Goodman Investment Counsel Inc. Dundee's capital markets and personal investment advisory services are carried out through the "Dundee Capital Markets" and "Dundee Goodman Private Wealth" divisions of its wholly owned subsidiary, Dundee Securities Ltd.  Dundee also owns and manages direct investments in its core focus areas and other select investments, through ownership, directly and indirectly, of both publicly listed and private companies.


'/>"/>
SOURCE TauRx Pharmaceuticals Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
2. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
3. Auxilium Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Healthcare Conference
4. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
5. AVANIR Pharmaceuticals To paticipate in two conferences in March
6. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
7. Adamis Pharmaceuticals Prevails in License Dispute Litigation
8. Cumberland Pharmaceuticals Reports 2012 Annual Financial Results
9. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
10. Spring Bank Pharmaceuticals Closes $10.5 million Series A Financing to fund Phase I Clinical Trials in HCV-infected Patients
11. StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
Breaking Medicine News(10 mins):